Pfizer announced that the European Commission, or EC, has granted marketing authorization for Litfulo to treat adults and adolescents 12 years of age and older with severe alopecia areata. Litfulo, a once-daily oral capsule, is the first medicine authorized by the EC to treat individuals as young as 12 years of age with severe alopecia areata. Litfulo is also the first and only treatment to selectively inhibit Janus kinase 3 and the tyrosine kinase expressed in hepatocellular carcinoma family of kinases.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PFE:
- Moderna (NASDAQ:MRNA) Plunges as COVID-19 Market Collapses
- Vaccine makers slip as Pfizer CFO sees weaker demand for COVID shots
- Essa Pharma initiates Phase 2 study of masofaniten/enzalutamide combo
- Novavax Stock (NASDAQ:NVAX) Has a Shot at Recovering
- Moderna to charge $129 for COVID shot, Pfizer $120, Bloomberg reports